NCT05263778 - Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions

Cardiovascular DiseasesNSTEMISTEMI

Interventions

DRUG

Bempedoic Acid / Ezetimibe Oral Tablet

Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks

DRUG

Placebo

Matching placebo by mouth once daily for 12 weeks

Trial Locations (1)

Kaiser Permanente Northern California Division of Research, Oakland